Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Has anyone had the opportunity to try any of Nanosphere's products? Are they effective? Superior?
Nice. Thank you very much.
Good point.
Seems to be a tremendous amount of support at .03. Don't understand what chart you are looking at to feel VATE is headed for .01. Please enlighten me.
This will land them on the New Cannabis Venture revenue ranking list, though their addition may only occur after the audited results come out. That is a rather exclusive list as far as cannabis companies go so the additional exposure is sure to increase investor interest.
Your right. It was followed up by another 2000 share trade a little latter at .0292.
That is interesting. Almost 500,000 shares traded in three minutes according to my TOS platform. 343,000 at .0293 to .03 two minutes before the 20 cent trade(s) and 150,000 at 20 cents. 600,632 total for the entire day. Haven't checked any other source to verify that.
Thanks for that.
This is for fiscal year 2018 over 2017? Seems obvious but I can't find a press release so I'm wondering if I understand this correctly.
OK. Thanks for that. I did assume there would be competition but it is good to hear we are the only publicly traded one.
Just received this headline in my email: Cannabiniers Rolls Out Cannabis-Infused Craft Beer Line In California. These guys are backed by CGC and Constellation Brands. I am invested in SIPC and just wondering where we are in relation to this?
Looks like today certainly makes your question even more relevant. Unfortunately I don't have the answer. No news that I can find.
Has anyone tried their LivRelief creams and do they work?
Do you have an opinion on their transdermal delivery system? Is it superior or a worthy competitor to all the others out there?
According to the information on Sedar the revenues are increasing year over year and Q over Q.
OS shares as of Sept 2018 47,459,450
Insider ownership approximately 20%
I too found the Seeking Alpha article to feel more like a "hit" piece.
I am just speculating but perhaps the reason Aurora is divesting itself of TGODF shares is the recent purchase of Whistler Medical Marijuana. Now that they own that do they really have a need for a relationship with TGODF? Since they now own a organic cannabis company they are raising cash by liquidating their shares of TGODF. Now does this say anything negative about TGODF or is it a tacit admission by Aurora that TGODF is on to something that is not really being pursued by that many companies?
And as to TGODF not being competitive in Canada they are setting up to dominate a niche within the larger cannabis market by concentrating on premium organic cannabis. There are not very many competitors in that specific market.
Like I said just speculation, and there are far more knowledgeable people on this board than I, but perhaps Aurora has seen the potential of TGODF and is attempting to enter that market on its own.
Good article. Thanks for that.
Thanks for that. The TOS doesn't show any activity. Of course 99 shares hardly qualifies as activity does it? LOL But maybe you can answer something else for me. What is the talk of it hitting $1.40?
Would someone mind filling me in? According to TD Ameritrade the stock did not even trade today. Was it halted today or have I missed something else?
Voluminous it is my young Padawan.
Yawn.....zzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzz
Has anyone on this board actually tried VitaStem? Does it do what they claim? It has very good reviews on Amazon....but we all know how that can be manipulated.
Yawn.....ZZZZZZZZ
Nor do I! Orphan drug designation and a 48 mil float would seem to be a recipe for something better than a two year low, especially when you take into consideration some of the prices paid for some rather dubious stocks in this industry group. Granted anything in the true Biotech area, by which I mean seeking to get FDA approval, is a longer term venture and most assuredly carries it's own risks. But receiving orphan drug approval should at least be an indication that this is a real company doing real research. I use TA to enter trades/investments so RVVTF is on my watch list and I believe it's day is coming. How soon? I'll let the stock tell me.
I went to Yahoo to check simply because it was quick. But the reason I checked was due to TD Ameritrade showing 358 million as well. I would much rather the float be the 50 million figure. I will usually check three or four sources for this information but I can't say as I have ever found a discrepancy of that magnitude. Has CANB ever done a reverse split? If that were the case then perhaps the 358/216 figures are simply outdated info. I am very new to this stock so I haven't done much research on it. The 50 mil figure would enable this stock to better emulate the performance of CV*I as some on this board have hoped for. I hope the OTCQB figure is correct.
For what its worth on Yahoo Finance the outstanding shares are listed as 358.55 million and the float as 216.95 million with insiders owning 31%.
These posts are the reason I hold on to my shares.
Just received this newsletter in the mail.
Dear Fellow Investors,
The newsletter I sent out earlier this week outlined in detail the strategic direction in which Alternate Health will be moving in the very near future. This follow up letter will report on the status of our other lines of business and how they fit into the company going forward. All of the effort, time, and resources spent in the development of these assets will give us a decided advantage in the cannabis space. Our decision to move aggressively into the cannabis market has been both timely and very well received by all who have called or written Alternate Health.
The opportunities being presented to us on a daily basis are not only exciting, but also have the potential to solidify Alternate Health as a leader in the cannabis industry in a short amount of time.
ZiApp Payment System
ZiApp is a payment processing engine specifically designed to handle the high-risk transactions that characterize the cannabis industry. Using a network of blockchain smart contracts and a fixed-exchange token, ZiApp offers a comprehensive solution to cannabis merchants who have struggled with traditional payment providers. ZiApp’s eWallet functionality is easily integrated with any retail Point of Sale system or online shopping cart, providing a comprehensive payment solution. This will be paramount in our Distribution Business as we work with farmers and dispensaries to streamline the cannabis supply chain and the movement of money going from raw materials to finished goods.
CanaPass/StatePass
CanaPass and its adaptations in the United States continue to gain traction in the medical-use cannabis market. In Florida, the recent approval from the state Department of Health and our agreement with Liberty Health Sciences has generated strong momentum. We have been actively growing our physician and patient base and have successfully processed online orders for medical cannabis through the FlorPass online shopping portal. While conversion to revenue has been slower than anticipated, we continue to enhance the system and do expect positive results in the future. The shopping portal and inventory management aspects of the system will transition nicely as we customize the software for California’s adult-use market.
Point of Sale
Our Point of Sale (POS) software was built as an extension of the CanaPass system to provide dispensaries and licensed providers with the ability to handle transactions and process payments in a brick-and-mortar retail environment. As we roll out our Distribution services in California, the POS system will be the competitive advantage for Alternate Health, giving us the ability to offer partner dispensaries a turn-key payment solution while seamlessly tracking inventory and consignment sales.
MLM Software
Our IT team has done a tremendous job in creating a Multi-Level Marketing software solution and we are now in the final stages of development. We are also in the process of evaluating several exciting CBD products to include in our offering. With the conclusion of our software development and selection of products, we will be ready to roll this program out in 2019. Our plans are to enter the CBD market when the time is right with the same level of enthusiasm that characterized our movement into the cannabis market.
Laboratory
The laboratory sector in the United States has undergone a major shift over the last 12 months. Independent labs have been forced to shut down due to new rules and decreases in payment amounts and adjudication percentages.
Alternate Health Labs was brought into the company as a cash flow generator while we matured our other lines of business. The lab performed as expected for the first 7-8 months, producing over $12 million in revenue. In late Summer of 2017, the changes in reimbursement rates began taking effect, as well as an onslaught of lawsuits against labs that were involved in the support of rural hospitals exercising their legal right to pursue a lab outreach program. Since then, the space has become increasingly litigious, with rules that have been honored for decades, changing overnight. Reimbursement rates for independent labs have fallen to unsustainable levels or cut off completely.
We tried desperately to find a way to stay involved in the industry, but our efforts were repeatedly met with pushback from the insurance companies. It is now time to move our resources away from the clinical space and incorporate our personnel, equipment, fixtures, and extensive knowledge base into the cannabis industry. In the coming months, we will be announcing work that is currently underway to accomplish this goal. Just as our other resources are dove-tailing nicely into the cannabis business model, we expect the lab will also be an ideal fit.
Conclusion
In the very near future, Alternate Health will be announcing managerial changes that will give us the leadership needed to take our Company forward. These changes will involve adding individuals with decades of experience and expertise in the cannabis sector. Also in this announcement, we will outline infrastructural changes as well as the movement of our offices to be more in line with the cannabis industry.
You will also notice a major change in our reporting to investors, as well as press releases. The new team will commit to a monthly investor newsletter that will detail all progress achieved in the period. This is an exciting time for Alternate Health. The next calendar year will prove to be the year that investors will be proud to be a partner in our progress.
Michael L. Murphy, MD
Chairman and Chief Executive Officer
November 23, 2018
Does anyone have a list of cannabis based biopharmaceutical companies that are attempting to get FDA approval for their products, as opposed to the many companies attempting to produce over the counter products but are also included in the biopharmaceutical sector? Not trying to put down the later I just want to concentrate on the former.
Thanks for that lead. Good interview. But I wouldn't characterize it as "analyst coverage". The Wall Street Reporter gets paid by the company for these presentations. Nevertheless it was a good interview with the CEO sounding experienced and competent.
"the moral side of things"? What about the moronic side of things? What clowns!
Thanks
I just received a Schedule 14C in my email tonight. If I understand it correctly the authorized shares will increase from 236,000,000 to 500,000,000. Any thoughts?
What do you see as the potential market size in dollars for these drugs? Any estimates out there?
Have a feeling that if the volume were high you would interpret that as a negative sign as well. I was a mail carrier and had a walkout route with a considerable number of retirees on it. I can remember all the old timers telling me about what the summer weather told us about the coming winter. If the summer was wet we were going to have a bad winter. If the summer was dry I was told that indicated the coming of a bad winter. If the summer was dry look out because we were going to have a bad winter. If the summer was cool.....well take a guess. Volume taken out of context can be read either way. Needs to be read in context.
Don't think there is any earth shattering news in the article for anyone already familiar with the company. But a little exposure in Forbes can't hurt.
The Stock price is reality for traders not necessarily so for investors. "Blood in the Streets" anyone? True or not we all have been told that the "smart money" sells to the retail traders when the price is going up and buys from them in the lower price ranges. Buffett doesn't invest in anything when it's expensive. And while this isn't value investing the investors here are buying potential not trading it. If you are a trader more power to you. The only thing I regret about this price drop is that I don't have any more money to be buying like crazy.
If you are trading then you should never argue with price. If you are investing then "blood in the streets" is your time.
There have been only three days since the first of June that have exceeded average volume by 50%. Now anyone can draw a line anywhere you want for what constitutes significant volume but that +50% is what IBD uses and I have found it to be significant in my trading as well. So I am down quite a bit on this but I don't see any reason to panic. The summer blahs combined with the concern over trade has pushed these stocks lower than expected.
Still like the looks of this company as far as its goals and plan.
However the decrease in revenue from $4,305,448.00 to 172,495.00 when comparing the 1st Q of '17 with the 1st Q of '18 isn't what I expected.
Maybe this has something to do with the spinoff. Anybody out there with more expertise than I have, which is just about anybody, care to comment?